Physician profile
Melissa M Wright
NPI 1992762504
$2,601.67
in general payments reported to CMS, 2019-2025
26 companies · $662 in 2025
The $662 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $156 · 2021: $635 · 2022: $411 · 2023: $154 · 2024: $256 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.43 | 2021-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $326.96 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $317.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $273.46 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $161.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biogen, INC. | $123.89 | 2025 | Zurzuvae, Skyclarys |
| Lundbeck LLC | $102.32 | 2021 | |
| Allergan, INC. | $89.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.70 | 2021-2022 | |
| Glaxosmithkline, LLC. | $68.60 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $61.11 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $41.15 | 2021-2022 | |
| Cepheid | $33.92 | 2025 | Genexpert |
| Vertex Pharmaceuticals Incorporated | $29.75 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.35 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $25.44 | 2019 | |
| Cochlear Americas | $24.65 | 2024 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Amarin Pharma, INC. | $23.64 | 2021 | |
| Sumitomo Pharma America, INC. | $23.11 | 2025 | Gemtesa |
| Jazz Pharmaceuticals INC. | $21.12 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.17 | 2021 | |
| Dexcom, INC. | $15.03 | 2024 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $12.48 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.29 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.70 | 2019 | |
| Mayne Pharma Commercial LLC | $7.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.